A novel coronavirus is the causative agent of the current epidemic of severe acute respiratory syndrome (SARS). Coronaviruses are exceptionally large RNA viruses and employ complex regulatory mechanisms to express their genomes. Here, we determined the sequence of SARS coronavirus (SARS-CoV), isolate Frankfurt 1, and characterized key RNA elements and protein functions involved in viral genome expression. Important regulatory mechanisms, such as the (discontinuous) synthesis of eight subgenomic mRNAs, ribosomal frameshifting and posttranslational proteolytic processing, were addressed. Activities of three SARS coronavirus enzymes, the helicase and two cysteine proteinases, which are known to be critically involved in replication, transcription and/or post-translational polyprotein processing, were characterized. The availability of recombinant forms of key replicative enzymes of SARS coronavirus should pave the way for high-throughput screening approaches to identify candidate inhibitors in compound libraries.
INTRODUCTION
Severe acute respiratory syndrome (SARS) is a lifethreatening form of pneumonia (Peiris et al., 2003a) . In the course of a few months in 2003, an epidemic emerged that has spread from its likely origin in Guangdong Province, China, to 32 countries. By 11 June 2003 more than 8400 cases and 789 deaths had been recorded by the World Health Organization. The rapid transmission by aerosols (and probably also the faecal-oral route) and the high mortality rate make SARS a global threat for which no efficacious therapy is available. There is now clear evidence that SARS is caused by a previously unknown coronavirus, provisionally termed SARS coronavirus (SARS-CoV) (Peiris et al., 2003b; Drosten et al., 2003; Ksiazek et al., 2003; Fouchier et al., 2003) . Genome sequences of SARS-CoV isolates obtained from a number of index patients have been published recently and provide important information on the organization, phylogeny and variability of the 29?7 kb positive-strand RNA genome of SARS-CoV (Rota et al., 2003; Marra et al., 2003; Ruan et al., 2003) . By analogy with other coronaviruses (Lai & Holmes, 2001; Siddell, 1995; Gorbalenya, 2001) , SARS-CoV gene expression is expected to involve complex transcriptional, translational and post-translational regulatory mechanisms, whose molecular details remain to be determined. SARS-CoV genome expression starts with the translation of two large replicative polyproteins, pp1a (486 kDa) and pp1ab (790 kDa), which are encoded by the viral replicase gene (21 221 nt) that comprises ORFs 1a and 1b (Fig. 1) . Expression of the ORF1b-encoded region of pp1ab is predicted to involve ribosomal frameshifting into the 21 frame just upstream of the ORF1a translation termination codon (Brierley et al., 1989) . The pp1a and pp1ab polyproteins are processed by viral proteinases to yield the functional components of the membrane-bound replicase complex (Ziebuhr et al., 2000) . In contrast to most other coronaviruses, which use three proteinase activities for replicase polyprotein processing (Ziebuhr et al., 2000; Gorbalenya, 2001) , SARS-CoV is predicted to encode only two proteinases (Rota et al., 2003; Snijder et al., 2003) . The replicase complex mediates both genome replication and transcription of a 'nested' set of subgenomic mRNAs. These mRNAs encode the structural was used to detect genomic and subgenomic SARS-CoV mRNAs. Poly(A)-containing RNA from HCoV-infected MRC-5 cells, which was hybridized with a 32 P-labelled probe specific for HCoV nt 26297-27273, was used as size marker (lane 3). (c) Alignment of SARS-CoV TRS elements identified by RT-PCR amplification and sequencing. Nucleotides matching the leader TRS are underlined. These sequences represent the leader-to-body fusion sites of subgenomic RNAs. The minimal TRS (59-ACGAAC-39) present in all functional TRSs is highlighted in grey. (d) Strategy used to identify the leader-to-body fusion sites of SARS-CoV subgenomic mRNAs. As an example, the RT-PCR amplification and sequence analysis of the fusion site of mRNA 3 is shown. The reverse transcription reaction was primed using an oligonucleotide specific for the body sequence. For the subsequent PCR, a leader-specific oligonucleotide was used in combination with a second, body-specific oligonucleotide. Sequence analysis of the resulting PCR product is shown in the bottom panel, with the TRS core sequence and translation initiation codon indicated.
proteins, S, E, M and N, and a set of accessory proteins whose number and sequence vary among different coronavirus species (Siddell, 1995) . The extraordinary size of the coronavirus replicase (poly)proteins, their generally large phylogenetic distance from those of other RNA viruses, and the presence of several predicted RNA processing activities which are not found in other positive-strand RNA viruses (Gorbalenya, 2001; Snijder et al., 2003) , indicate that coronavirus replicases are of an unparalleled complexity. The underlying biological mechanisms and functional constraints that determine the evolution and conservation of these unique activities remain to be elucidated.
In this study, we used the Frankfurt 1 isolate, the sequence of which we report here, to characterize critical steps of SARSCoV gene expression, such as synthesis of subgenomic mRNAs, translation of key replicative proteins by frameshifting and post-translational processing. Proteolytic processing by viral proteinases provides the active components of the viral replicase complex. The results we obtained were used to rank possible targets for therapeutic intervention in SARS and other coronavirus infections.
METHODS
Preparation of SARS-CoV RNA. Vero or Vero E6 cells (1610 7 ) were infected with SARS-CoV (Drosten et al., 2003) (isolate Frankfurt 1, fifth passage in cell culture) at an m.o.i. of 0?01. Two days after infection, intracellular poly(A)-containing RNA was prepared as described by Thiel et al. (2001) . RNA isolated from respiratory tract and stool specimens was prepared using the QIAamp and QIAamp stool kit (Qiagen), respectively, according to the manufacturer's instructions.
Sequencing of the SARS-CoV (Frankfurt 1) RNA genome. To determine the SARS-CoV genomic sequence, a set of overlapping RT-PCR products with an average size of 2 kb encompassing the entire genome was generated as described by Thiel et al. (1997) . To generate RT-PCR products containing the exact 39-terminal sequence of SARS-CoV genomic RNA, reverse transcription was primed using oligonucleotide OLV1/57 (59-GCCGGCGCCAGCGAGGAGGCTGG-GACCATGCCGGCCTTTTTTTTTTTTTTTTTT-39) and PCR was done using oligonucleotides PCR-L (59-23 GGAAAAGCCAACCAACCTC-GATCTC 47 -39) and OLV1/58 (59-ACGTTCTAGAGCCCAGCCGGCG-CCAGCGAGGAGGCT-39). To generate RT-PCR products containing the exact 59-terminal sequence the FirstChoice RLM-RACE Kit (Ambion) was used according to the manufacturer's instructions with the following modifications. A synthetic RNA corresponding to human coronavirus 229E (HCoV-229E) nt 1-600 was used as RNA adapter and reverse transcription was primed using oligonucleotide S65 (59-439 CTTTTTCCAGCTCTACTAGACCAC 416 -39). Outer PCR was done using oligonucleotides 240up (59-CCTTACTCGAGGTTCCG-TCTCGTG-39) and S132 (59-341 ACGTCTCTAACCTGAAGGACA-GGC 318 -39); inner PCR was done using oligonucleotides Oli5 (59-GCGAGGCCGCTAGCAATGG-39) and S133 (59-235 CTAGGTA-TGCTGATGATCGACTGC 212 -39). All RT-PCR products served as template for sequencing analysis using a total number of 149 sequencing primers and the BigDye Terminator v3.1 Cycle Sequencing Kit. Sequencing products were detected using an ABI PRISM 3100 Genetic Analyser (Applied Biosystems) and computerassisted analysis of sequencing data was facilitated by the Lasergene bio-computing software (DNASTAR). In vitro transcription and translation. In vitro transcription reactions were done using the RiboMAX Large Scale RNA Production System-T7 (Promega) and m 7 G(59)ppp(59)G cap structure analogue as described by Thiel et al. (2001) . In vitro translation reactions were done in rabbit reticulocyte lysate (Promega) using in vitrotranscribed RNA (Ziebuhr & Siddell, 1999) . Alternatively, DNA templates containing a T7 promoter were transcribed and translated using the TNT T7-Coupled Reticulocyte Lysate System (Promega). To analyse the SARS-CoV frameshifting element, a DNA fragment corresponding to SARS-CoV nt 12955-13961 was amplified by RT-PCR using oligonucleotides S25 (59-17511 CAATTTCAGCAGGACAA-CGGCGAC 17488 -39; RT reaction), JZ464 (59-AATAATACGACTCA-CTATAGGGAACCATGGCTGGAAATGCTACAGAAGTACCTGC-39, PCR sense primer) and JZ465 (59-AAAGAATTCTTAACGCATAGC-ATCGCAGAATTGTAC-39; PCR antisense primer). To generate a DNA fragment with mutated 'slippery' sequence ( 13392 UGUAGCC 13398 ), two PCRs were done using oligonucleotides S59 (59-12916 ATGGTGCTG-GGCAGTTTAGCTGCT 12939 -39; PCR 1, sense primer), JZ467 (59-AAAAGGTCTCCGGCTAGAAACGTTGATGCATCCGCAGAC-39; PCR 1, antisense primer), JZ466 (59-AAAAGGTCTCTAGCCGGGTTTGCG-GTGTAAGTGCAGCCC-39; PCR 2, sense primer) and S91 (59-14039 -TACGAAATCACCGAAATCGTACCA 14016 -39; PCR 2, antisense primer). PCR products 1 and 2 were cleaved with BsaI restriction endonuclease and ligated using T4 DNA ligase. The ligation product was used as template to amplify a DNA fragment corresponding to SARS-CoV nt 12955-13961 (with mutated 'slippery' sequence) using oligonucleotides JZ464 and JZ465.
For in vitro transcription-translation of the 3CL pro substrate representing nsp7-nsp10 of SARS-CoV (Ser-3837-Gln-4369), the corresponding coding sequence of SARS-CoV was amplified using primers JZ433(59-AATAATACGACTCACTATAGGGCGAACCATGTCTAAAA-TGTCTGACGTAAAGTGCA-39) and JZ434 (59-AAAGAATTCTTACT-GCATCAAGGGTTCGCGGAGTTG-39). The upstream primer contained a T7 RNA polymerase promoter. For in vitro transcription-translation of the pp1a/pp1ab sequence Lys-737-Ser-1858, containing the PL2 pro domain and the presumed nsp2|3 cleavage site, the corresponding coding sequence was amplified by RT-PCR using primers AP91 (59-TAATACGACTCACTATAGGGACGGGAACACCATGGCAAAAGA-AGTAACCTTTCTTGAAGGT-39) and S77 (59-5839 ACGACACAGGC-TTGATGGTTGTAG 5816 -39). To introduce a PL2 pro active-site mutation (Cys-1651 to Ala) in this sequence, two PCRs were done using (1) primers AP91 and AP94 (59-ATAGCTCTTCATGCATTGTTATCAG-CCCATTTAATTGA-39) and (2) AP 95 (59-ATAGCTCTTCAGCATA-TTTGTCTAGTGTTTTATTAGCA-39) and S77. Following digestion of the PCR products obtained with SapI and ligation with T4 DNA ligase, the pp1a/pp1ab coding sequence Lys-737-Ser-1858 was re-amplified using the ligation product as a template and primers AP91 and S77. The sequences of PCR products used as templates for in vitro transcription were confirmed by nucleotide sequencing.
Protein expression, purification, and activities. Plasmid construction, expression in Escherichia coli and purification of the maltose-binding protein (MBP) fusion proteins MBP-HCoV 3CL pro and MBP-TGEV (porcine transmissible gastroenteritis virus) 3CL
pro , and the corresponding active-site mutants, MBP-HCoV 3CL
pro _ C3109V and MBP-TGEV 3CL pro _C3022A, have been described previously (Ziebuhr et al., 1995 . The same approach was taken to express the SARS-CoV pp1a/pp1ab amino acids 3241-3545 (i.e. the SARS-CoV 3CL pro domain lacking the two C-terminal residues, Phe-3545 and Gln-3546) and the corresponding active-site Cys-3385-to-Ala mutant. The coronavirus proteinases were released from MBP by factor Xa cleavage and used, according to previously published protocols (Ziebuhr & Siddell, 1999) , in trans-cleavage assays with in vitro-translated substrate or 0?5 mM of synthetic 15-mer peptides whose sequences were derived from the N-terminal TGEV and mouse hepatitis virus (MHV) 3CL pro autoprocessing sites (Seybert et al., 1997; . The SARS-CoV helicase (SARS-CoV HEL, pp1ab residues Ala-5302-Gln-5902) and a control protein, SARS-CoV HEL_KA, in which the conserved Lys of the Walker A box (SARS-CoV pp1ab K 5589 ) was replaced by Ala, were expressed and purified in a similar way. Briefly, the helicase-coding region was amplified by RT-PCR using primers JZ425 (59-GCTGTAGGTGCTTGTGTATTGTGC-39) and JZ426 (59-AAAACTGCAGTTATTGTAATGTAGCCACATTGCGACGTGG-39). The PCR product was digested with PstI and inserted in XmnI-and PstI-digested pMal-c2 DNA (New England Biolabs). The mutation was introduced using a PCR-in vivo recombination method (Yao et al., 1992) . Expression and purification of MBP-HEL and MBP-HEL_KA were done essentially as described for the HCoV-229E helicase Seybert et al. (2000a) . The unwinding reaction was done for 30 min at 25 uC in buffer A (HEPES/KOH, pH 7?4, 10 % glycerol, 5 mM magnesium acetate, 2 mM dithiothreitol and 0?1 mg BSA ml 21 ) using 10 nM of substrate and various concentrations of MBP-HEL (8, 80 and 800 nM) and MBP-HEL_ KA (800 nM), respectively. The reaction products were analysed on polyacrylamide/TBE gels, which were exposed to X-ray film. ATPase reactions were done in buffer A for 5 min at 25 uC using the following concentrations: MBP-HEL and MBP-HEL_KA each at 0?8 mM, 10 mM [a- 
RESULTS AND DISCUSSION

Genomic sequence of SARS-CoV Frankfurt 1
Here we report the complete genome sequence of a SARSCoV isolate, Frankfurt 1, obtained from a 32-year-old male physician who was admitted with typical symptoms of SARS to the isolation ward of the Frankfurt University hospital on 15 March 2003 (Drosten et al., 2003) . The virus was propagated in African green monkey kidney (Vero and Vero E6) cells, poly(A)-containing RNA was isolated and used for reverse transcription and PCR amplification with primers derived from the SARS-CoV TOR2 sequence. The exact genome termini were determined by 59 and 39 RACE methods. The complete sequence encompasses 29 727 nt [excluding the 39 poly(A) tail] and has been deposited with the GenBank database (accession no. AY291315). Comparison of the genomic sequence of SARS-CoV Frankfurt 1 with 17 previously sequenced SARS-CoV isolates (TOR2, AY274119.3; Urbani, AY278741.1; CUHK-W1, AY278554.2; BJ01, AY278488.2; HKU-39849, AY278491.2; BJ02, AY278487.3; BJ03, AY278490.3; BJ04, AY279354.2; GZ01, AY278489.2; SIN2679, AY283796.1; SIN2500, AY283794.1; ZJ01, AY297028.1; SIN2677, AY283795.1; TW1, AY291451.1; CUHK-Su10, AY282752.1; SIN2748, AY283797.1; SIN2774, AY283798.1) revealed four nucleotide exchanges that have not been described previously for other SARS-CoV isolates and thus seem to be specifically linked to the Frankfurt 1 isolate (A2557, U11448, U24933, U28268). Three of these (may) lead to amino acid substitutions (assuming all predicted ORFs are expressed). Interestingly, the sequence analysis also revealed that, upon SARS-CoV propagation in cell culture (starting with passage 3), a virus variant emerged in which a 45 nt, in-frame sequence (27670-27714) was deleted from ORF7b, thus reducing the genome size to 29 682 nt. The deletion provides evidence that SARS-CoV may undergo rapid adaptation in cell culture. The biological significance of this observation remains to be investigated in detail.
Subgenomic mRNA synthesis
Coronaviruses (and arteriviruses) use a unique strategy to synthesize a set of subgenomic RNAs with common 59 and 39 sequences (Fig. 1) (Lai & Holmes, 2001; Siddell, 1995; Pasternak et al., 2001; Sawicki & Sawicki, 1998) . Each mRNA contains a short 59-terminal 'leader' sequence derived from the 59 end of the genome. The fusion of the noncontiguous sequences is currently believed to be achieved by a discontinuous step during minus-strand synthesis and involves transcription regulatory sequences (TRSs). In addition to the TRS at the 39 end of the leader sequence (leader TRS), TRSs are located upstream of the genes in the 39-proximal part of the genome (body TRSs) (Lai & Holmes, 2001; Siddell, 1995; Sawicki & Sawicki, 1998) . To confirm that SARS-CoV also uses this discontinuous transcription strategy and to elucidate the molecular details of the resulting subgenomic RNAs, we analysed intracellular RNA synthesis by Northern blotting and determined the SARS-CoV mRNA sequences at the sites where the common 59 leader is fused to the various 39 'body' sequences, thus generating the subgenomic RNAs identified in SARS-CoV-infected cells. A Northern blot analysis using poly(A)-containing RNA isolated from SARS-CoV-infected cells and a probe specific for the 39-proximal 794 nt revealed the synthesis of as many as nine RNAs, with RNA 1 representing the viral genome of 29?7 kb. The sizes of the subgenomic mRNAs were assessed using the previously characterized HCoV-229E RNAs as markers. To provide conclusive evidence for the presence of common 59 leader sequences in each of the SARS-CoV mRNAs and to determine the leader-to-body fusion sites precisely, the 59-proximal regions of mRNAs 2 to 9 were amplified by RT-PCR and sequenced. The amplification strategy used in these experiments is illustrated for subgenomic mRNA 3 in Fig. 1(d) . In some cases we obtained, in addition to the expected RT-PCR product for a given mRNA, larger PCR products that corresponded to the expected RT-PCR products for the next largest subgenomic mRNAs. Sequence analysis of these products confirmed their identity unambiguously. The data obtained by RT-PCR amplification, sequence analysis and Northern blotting consistently suggest that SARS-CoV produces eight subgenomic mRNAs. Furthermore, the study revealed that a minimal consensus sequence, 59-ACGAAC-39, is sufficient to direct the synthesis of SARS-CoV subgenomic mRNAs, most probably by base-pairing of its negative-stranded counterpart to the leader TRS during minus-strand synthesis. The number of identical nucleotides in leader TRS and body TRS regions varies between 6 and 11 (Fig. 1c) , but there is no clear correlation between the extent of sequence complementarity and abundance of a given mRNA (Fig. 1b  and 1c ), indicating that additional factors (such as sequence elements, RNA structures, proteins) are involved in regulating the relative abundance of viral mRNAs. It is tempting to speculate that the transcription mechanism used by coronaviruses, arteriviruses and (in part) toroviruses (van Vliet et al., 2002) has evolved to allow the production of a large set of structural and nonstructural (some of them probably virulence-associated) proteins (de Haan et al., 2002) , whose abundance can be regulated at the transcriptional level. Regulation of coronavirus gene expression can be even further extended by the presence of additional, downstream ORFs in the 59 unique regions of some of the subgenomic mRNAs. These are generally expressed by leaky scanning of ribosomes or internal ribosomal entry (Lai & Holmes, 2001; Siddell, 1995; Thiel et al., 1994) . As shown in Fig. 1 , SARS-CoV also produces four subgenomic RNAs (mRNA 3, 7, 8, 9) with downstream ORFs in their unique regions. The functions of the corresponding SARS-CoV gene products remain to be characterized. The observed 45 nt deletion in the putative ORF7b (see above) appears to suggest that at least one of these gene products is dispensable in cell culture. However, it cannot be excluded that the 15 aa deletion from the ORF7b gene product gives rise to an active (or partially active) protein.
Translation
The structures of SARS-CoV mRNAs (Fig. 1 ) lead us to suggest that five of the nine SARS-CoV RNAs are functionally bicistronic. For most of them, the mechanisms used to express the downstream ORFs remain to be determined. On the basis of the available data for other coronaviruses (Brierley et al., 1989; Eleouet et al., 1995; Herold et al., 1993; Kocherhans et al., 2001) , it seemed likely that ORF1b expression from the genomic RNA would involve 21 ribosomal frameshifting, a process that essentially depends on two elements, known as the 'slippery' sequence, i.e. the site where the ribosomes shift into the 21 reading frame, and a complex RNA pseudoknot structure (Brierley et al., 1989 . Analysis of the SARS-CoV sequence flanking the ORF1a termination codon revealed a putative SARSCoV frameshifting element comprised of a putative 'slippery' sequence ( 13392 UUUAAAC 13398 ) and, further downstream, stretches of complementary sequences that can be modelled to form a typical pseudoknot structure (Fig. 2a) . To confirm that these elements mediate frameshifting in SARS-CoV and to define the frameshift site precisely, we synthesized RNAs containing the SARS-CoV frameshift region and produced a mutant version of the presumed 'slippery' sequence ( 13392 UUUAAAC 13398 R 13392 UGUAGCC 13398 ). As shown in Fig. 2(b) , efficient ribosomal frameshifting depended on an essentially unmodified 13392 UUUAAAC 13398 sequence, supporting the prediction that this sequence constitutes the actual slippage site.
Polyprotein processing by PL2 pro
Translation of pp1a and its C-terminally extended version, pp1ab (see above), is coupled with extensive proteolytic processing by viral proteinases (Fig. 3) . Except for infectious bronchitis virus (IBV) (Liu et al., 1995; Lim et al., 2000) , all previously characterized coronaviruses encode two (paralogous) papain-like cysteine proteinases (PL1 pro and PL2 pro ), which cleave the N-proximal polyprotein regions at three sites (Gorbalenya et al., 1991; Bonilla et al., 1997; Baker et al., 1989; Kanjanahaluethai & Baker, 2000; Ziebuhr et al., 2001; Herold et al., 1998) , while the 3C-like cysteine proteinase (3CL pro ; also called main proteinase, M pro ) cleaves the central and C-proximal regions at 11 conserved sites (Ziebuhr et al., 2000) . The conservation of both the positions and sequences of coronavirus pp1a/pp1ab cleavage sites allows the substrate specificities of proteinases of newly identified coronaviruses to be predicted (Fig. 3) . Thus, it has been proposed that SARS-CoV PL2 pro cleaves three sites in the N-proximal region of pp1a/pp1ab (Snijder et al., 2003) . This is similar to IBV, where one proteinase, PL2
pro , cleaves two sites in this region, but stands in contrast to other coronaviruses (e.g. HCoV-229E and MHV), which cleave three sites by using two PL pro activities, PL1 pro and PL2 pro . To establish the proteolytic activity of the SARS-CoV PL2 pro domain at one of the predicted sites, we expressed, by in vitro translation, the SARS-CoV pp1a/pp1ab amino acids 737-1858 along with a mutant construct in which the presumed active-site Cys nucleophile of PL2 pro was replaced by Ala (C-1651-A). The data shown in Fig. 4 strongly suggest that rapid, probably co-translational autoprocessing of the wild-type protein occurred. The apparent sizes of the major products of~125 (C-1651-A) and~115 kDa (wildtype sequence) are consistent with cleavage at the predicted site, 818 Gly|Ala 819 (Snijder et al., 2003) . Probably due to the presence of only two Met residues in the N-terminal cleavage product, the expected N-terminal 9 kDa protein could not be detected convincingly. Comparative analysis of coronavirus PL pro cleavage sites revealed that the (predicted) SARS-CoV PL2 pro sites are more conserved than the equivalent HCoV-229E PL1 pro and PL2 pro sites (Fig. 5) . The poor conservation of HCoV-229E PL pro cleavage sites probably results from the overlapping substrate specificities of PL1 pro and PL2 pro , which we reported previously (Ziebuhr et al., 2001) . Consistent with the hypothesis that conservation of only one PL pro domain is linked to an increase in specificity, we also find that the IBV PL2 pro cleavage sites are much better conserved than the corresponding HCoV-229E PL1 pro /PL2 pro sites (Fig. 5) . The observed narrow substrate specificity of the SARS-CoV PL2 pro will certainly facilitate the development of selective proteinase inhibitors. 
Polyprotein processing by 3CL pro
At present the viral main proteinase, 3CL
pro , is the bestcharacterized coronavirus enzyme. Its essential function is reflected by the fact that it cleaves as many as 11 sites in the replicase polyproteins and also releases the key replicative functions, such as the RNA-dependent RNA polymerase and the helicase, from the polyprotein precursors (Gorbalenya et al., 1989a; Ziebuhr et al., 2000) . Furthermore, 3CL pro is the only coronavirus protein for which structure information is available (Anand et al., 2002 (Anand et al., , 2003 . Coronavirus
3CL
pro s are cysteine proteinases with interesting properties. They feature a serine proteinase (chymotrypsin)-like two-bbarrel fold but employ a catalytic Cys-His dyad instead of the classical Ser-His-Asp triad. Furthermore, they possess a third, C-terminal domain composed of five a-helices. Our previous work has shown that the 3CL pro substrate specificities are conserved among the three established groups of coronaviruses and comparison of the previously known coronavirus cleavage sites with those identified in the SARS-CoV polyproteins ( Fig. 3; Fig. 6a Fig . 6 . Conservation of coronavirus main proteinase substrate specificities. Conservation of 3CL pro sites in polyproteins of SARS-CoV (b) and six other coronaviruses (a). Two separate multiple, gap-free 18-aa-long alignments including the P9-P99 positions of the sites (presumably) cleaved by the 3CL pro domains of six coronaviruses (transmissible gastroenteritis virus, NC_002306; HCoV-229E; porcine epidemic diarrhoea virus, NC_003436; mouse hepatitis virus A59, NC_001846; bovine coronavirus, AF391542; IBV-B) and SARS-CoV were converted into two sequence logo (Schneider & Stevens, 1990) presentations. In the logos, the height of each letter (amino acid residue) is proportional to its frequency at the specific position, with the highest-frequency residue being on top of the stack. The height of the entire stack is proportional to the information at this position which is measured in bits, with the upper limit of information at any position being equal to 4?32 bits. Amino acid residues are coloured in the following groups: light-green -S, T, C; orange -N, Q; red -D, E; blue -K, R, H; brown -W, F, Y; black -A, L, I, V, M; pink -P; green -G. The most conserved and important positions have relatively high letter heights and are easily recognized, along with the individual and group residues occupying them. (c) Representation of the SARS-CoV pp1a/pp1ab cleavage sites predicted to be cleaved by PL2 pro (shown in blue) or 3CL pro (red). Also shown is the structure of the substrate used in the transcleavage assay. The P1 and P19 residues of predicted cleavage sites are given. SARS-CoV pp1a/pp1ab residues were translated in vitro and incubated for 180 min at 25˚C (lanes 1, 6, 11); or were incubated for 30 min (lanes 2, 7, 12), 60 min (lanes 3, 8, 13) and 180 min (lanes 4, 9, 14) , respectively, with bacterially expressed SARS-CoV (lanes 2-4), TGEV (lanes 7-9) and HCoV (lanes 12-14) main proteinases. As controls, the corresponding active-site Cys- and b) suggests conservation of the P4 (Ser, Thr, Val, Pro, Ala), P2 (Leu, Ile, Val, Phe, Met), P1 (Gln) and P19 (Ser, Ala, Gly, Asn, Cys) residues, all of which have previously been proposed to define the coronavirus 3CL pro substrate specificity (Ziebuhr et al., 2000) . In SARS-CoV, the strong preference for Leu at the P2 positions of substrates is less prominent and the more frequent use of Phe may indicate a slightly larger S2 subsite. There are also conservative changes in the P4 and P19 positions of SARS-CoV 3CL pro substrates. To determine whether these subtle variations result in differences in substrate specificity, we characterized the SARS-CoV 3CL pro specificity in more detail and compared it with that of the well-characterized HCoV-229E and TGEV enzymes. SARS-CoV 3CL pro was expressed as an MBP fusion protein, an approach that had proven suitable for the production of active coronavirus 3CL pro s (Seybert et al., 1997; Ziebuhr et al., 1997; . Following factor Xa cleavage of the purified fusion protein, the released SARS-CoV 3CL pro was used in trans-cleavage experiments with in vitro-translated substrates (Fig. 6d) or synthetic peptides derived from group 1 (TGEV) and group 2 (MHV) N-terminal 3CL pro autoprocessing sites Seybert et al., 1997) (data not shown). The substrate derived from the C-terminal pp1a sequence was chosen because it contained as many as three cleavage sites, allowing side-by-side comparison of cleavage efficiencies at different sites. Furthermore, the fact that the proteolytic processing of this region has already been studied extensively in other coronaviruses (Ziebuhr & Siddell, 1999; Bost et al., 2000) allowed safe predictions on SARS-CoV 3CL pro cleavage products in this region. As shown in Fig. 6(d) , the cleavage products (and several intermediate products) predicted to be released by 3CL pro cleavage ( Fig. 3 ; Snijder et al., 2003) were readily detectable upon incubation of the translation product with purified SARS-CoV 3CL
pro , but not with the active-site Cys-to-Ala mutant. Significantly, nearly identical cleavage kinetics were observed when purified TGEV and HCoV-229E 3CL pro s (instead of SARS-CoV 3CL pro ) were incubated with the SARS-CoV-derived substrate. Again, as expected, no cleavage was observed with the active-site Cys-to-Ala (Val) mutants. Consistent data were also obtained in peptide cleavage assays, where the SARS-CoV, HCoV-229E and TGEV enzymes were shown to cleave TGEV and MHV substrates with equal efficiencies (data not shown). The data conclusively demonstrate the proteolytic activity of the expressed SARS-CoV protein and, even more importantly, suggest conservation of coronavirus 3CL pro substrate specificities.
Essential proteins involved in replication and transcription
Characterization of individual protein functions involved in coronavirus replication and transcription is still at a very early stage. Thus, for example, there is essentially no experimental data on coronavirus RNA polymerase activities. Only the helicase has been characterized to some extent (Seybert et al., 2000a) . On the basis of seven conserved sequence motifs, the coronavirus enzyme has been classified as belonging to the helicase superfamily 1 (Gorbalenya et al., 1989b) . We previously reported that helicases of HCoV-229E and the arterivirus equine arteritis virus (EAV) possess polynucleotide-stimulated NTPase activity and 59-to-39 RNA and DNA duplex-unwinding activities (Seybert et al., 2000a, b) . Both coronavirus and arterivirus helicases require an N-terminal (putative) metal-binding domain, consisting of at least 12 conserved Cys and His residues, for activity. The domain is essential for replication, transcription and virion morphogenesis (as demonstrated for EAV) (van Dinten et al., 2000) . The SARS-CoV helicase is predicted to be released from pp1ab by 3CL pro -mediated cleavages of the 5301 Gln|Ala 5302 and 5902 Gln|Ala 5903 dipeptide bonds ( Fig. 3 ; Snijder et al., 2003) . We therefore expressed SARSCoV pp1ab residues 5302-5902, representing the 67 kDa helicase together with its N-terminal metal-binding domain, in a bacterial expression system. A fusion protein, consisting of MBP and the SARS-CoV helicase domain, was purified by amylose affinity chromatography and used in ATPase and duplex-unwinding assays. Fig. 7 (a) shows that this fusion protein (MBP-HEL), but not a control protein (MBP-HEL_KA) in which the conserved Lys residue of the Walker A box (Walker et al., 1982) was replaced by Ala, had ATPase activity that could be stimulated by poly(U). The protein also had DNA duplex-unwinding activity (Fig. 7b) . This is consistent with the previously characterized HCoV-229E helicase (Seybert et al., 2000a) , which also had revealed a high promiscuity with respect to the substrates used. Thus, both DNA and RNA duplexes were found to be unwound by the HCoV-229E helicase with similar efficiency and all types of nucleotide and ribonucleotide cofactors were used (Seybert et al., 2000a; K. A. Ivanov, V. Thiel & J. Ziebuhr, unpublished data) .
Conclusion
The study provides the first experimental data on both mechanisms and enzymes involved in SARS coronavirus genome expression and extends our understanding of the phylogenetic relationship between SARS-CoV and other coronaviruses. Given the unresolved global threat of the SARS-CoV epidemic, the rapid development of efficacious antiviral drugs is urgently needed. From this perspective, our results provide insights into key replicative enzymes which represent attractive targets for antiviral therapy. The methods established here for the large-scale production of recombinantly expressed, active SARS-CoV enzymes pave the way for high-throughput screening approaches to identify candidate inhibitors in large compound libraries. Thus, for example, the DNA duplex-unwinding activity of the SARS-CoV helicase should allow the use of highthroughput DNA (instead of RNA)-based helicase assays, which will significantly facilitate the search for (currently not evident) inhibitors. Furthermore, the SARS-CoV PL2 pro is shown to possess an (among coronaviruses PL pro s) unusually narrow substrate specificity, making this protein another suitable target for rational drug design. At present, the SARS-CoV 3CL pro represents the most promising target. Both the availability of crystal structures for TGEV and HCoV-229E coronavirus 3CL pro enzymes, which share their substrate specificities with that of SARS-CoV 3CL pro , and the availability of active SARS-CoV 3CL pro for highthroughput screening assays, should provide an excellent basis for the rapid identification of candidate drugs suitable for SARS therapy. 
